International Journal of Radiation Oncology * Biology * Physics
Volume 59, Issue 3 , Pages 684-690 , 1 July 2004

Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer

  • Junichi Hiratsuka, M.D.

      Affiliations

    • Department of Radiation Oncology, Kawasaki Medical School, Kurashiki, Japan
    • Corresponding Author InformationReprint requests to: Junichi Hiratsuka, M.D., Department of Radiation Oncology, Kawasaki Medical School, Matsushima 577, Kurashiki 701-0192 Japan. Tel: (+81) 86-462-1111; Fax: (+81) 86-462-1199
    • ,
  • Yoshimasa Jo, M.D.

      Affiliations

    • Department of Urology, Kawasaki Medical School, Kurashiki, Japan
    • ,
  • Kenji Yoshida, M.D.

      Affiliations

    • Department of Radiation Oncology, Kawasaki Medical School, Kurashiki, Japan
    • ,
  • Naomi Nagase, Ph.D.

      Affiliations

    • Department of Radiation Oncology, Kawasaki Medical School, Kurashiki, Japan
    • ,
  • Masato Fujisawa, M.D.

      Affiliations

    • Department of Urology, Kawasaki Medical School, Kurashiki, Japan
    • ,
  • Yoshinari Imajo, M.D.

      Affiliations

    • Department of Radiation Oncology, Kawasaki Medical School, Kurashiki, Japan

Received 25 June 2003 ,Revised 20 October 2003 ,Accepted 21 November 2003.

References 

  1. Brachman DG, Thomas T, Hilbe J, et al.  Failure-free survival following brachytherapy alone for T1-2 prostate tumors in 2222 patients (Results from a single practice). Int J Radiat Oncol Biol Phys. 2000;48:111–117
  2. Beyer DC, Priestley JB. Biochemical disease-free survival following 125I prostate implantation. Int J Radiat Oncol Biol Phys. 1997;37:559–563
  3. Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal iodine 125I implantation for stage T1/T2 prostate carcinoma. J Clin Oncol. 1996;14:449–453
  4. Blasko JC, Wallner K, Grimm PD, et al.  Prostate specific antigen based disease control following ultrasound guided I-125 implantation for stage T1/T2 prostatic carcinoma. J Urol. 1995;154:1096–1099
  5. Radge H, Elgamal AA, Snow PB, et al.  Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer. 1998;83:989–1001
  6. Bertermann H, Brix F. Ultrasonically guided interstitial high dose rate brachytherapy with Ir-192: Technique and preliminary results in locally confined prostate cancer. In:  Martinez AA,  Orton CG,  Mould R editor. Brachytherapy HDR and LDR (Remote afterloading state of art). Leerson, The Netherlands: Nucletron International BV; 1990;p. 281–303
  7. Mate TP, Kwiatkowski TM, Hatton JW. Remote HDR afterloading brachytherapy of the prostate (A preliminary report). Act Selectron Brachyther J. 1990;4:65–67
  8. Martinez AA, Gonzalez J, Stronberg J, et al.  Conformal prostate brachytherapy (Initial experience of a phase I-II dose-escalation trial). Int J Radiat Oncol Biol Phys. 1995;33:1019–1027
  9. Yoshioka Y, Nose T, Yoshida K, et al.  High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer (Treatment description and preliminary results of a phase I/II clinical trial). Int J Radiat Oncol Biol Phys. 2000;48:675–681
  10. Hanks GE, Buzydlowski J, Sause WT, et al.  Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06. Int J Radiat Oncol Biol Phys. 1998;40:765–768
  11. Asbell SO, Martz KL, Shin KH, et al.  Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG 77-06, a phase III study for T1bN0M0(A2) and T2N0M0(B) prostate carcinoma. Int J Radiat Oncol Biol Phys. 1998;40:769–782
  12. Martinez AA, Kestin LL, Stronberg JS, et al.  Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer (The William Beaumont phase dose-escalating trial). Int J Radiat Oncol Biol Phys. 2000;47:343–352
  13. American Society for Therapeutic Radiation and Oncology Consensus Panel . Consensus statement (Guidelines for PSA following radiation therapy). Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  14. Lawton CA, Won M, Pilepich MV, et al.  Long-term sequelae following external beam irradiation for adenocarcinoma of the prostate (Analysis of RTOG studies 7506 and 7706). Int J Radiat Oncol Biol Phys. 1991;21:935–939
  15. Deger S, Dinges S, Roigas J, et al.  High-dose rate iridium192 afterloading therapy in combination with external beam irradiation for localized prostate cancer. Techn Urol. 1997;3:190–194
  16. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  17. Stromberg J, Martinez A, Gonzalez J, et al.  Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer (Treatment description and preliminary results of a phase I/II clinical trial). Int J Radiat Oncol Biol Phys. 1995;33:161–171
  18. Borghede G, Hedelin H, Holmang S, et al.  Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostate carcinoma. Radiother Oncol. 1997;44:237–244
  19. Mate TP, Gottesman JE, Hatton J, et al.  High dose-rate afterloading 192Iridium prostate brachytherapy (Feasibility report). Int J Radiat Oncol Biol Phys. 1998;41:525–533
  20. Syed NAM, Puthawala AA, Barth N, et al.  High dose rate brachytherapy in the treatment of carcinoma of the prostate (Preliminary results). J Brachytherapy Int. 1997;13:315–331
  21. Roach M, Lu JD, Lawton LC, et al. A phase III trial comparing whole-pelvic (WP) to prostate only (PO) radiotherapy and neoadjuvant total androgen suppression (TAS): Preliminary analysis of RTOG 9413. Proceedings of the 43rd Annual ASTRO Meeting, 2001. p. 3
  22. Seaward SA, Weinberg V, Lewis P, et al.  Improved freedom from PAS failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 1998;42:1055–1062
  23. Galalae RM, Kovacs G, Schultze J, et al.  Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 2002;52:81–90
  24. Kestin LL, Goldstein NS, Vicini FA, et al.  Treatment of prostate cancer with radiotherapy (Should the entire seminal vesicles be included in the clinical target volume?). Int J Radiat Oncol Biol Phys. 2002;54:686–697
  25. Katcher J, Kupelian PA, Zippe C, et al.  Indications for excluding the seminal vesicles when treating clinically localized prostatic adenocarcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys. 1997;37:871–876
  26. Kovacs G, Galalae R, Loch T, et al.  Prostate preservation by combined external beam and HDR brachytherapy in nodal negative prostate cancer. Strahlenther Oncol. 1999;175(Suppl.):87–88
  27. Dinges S, Deger S, Koswig S, et al.  High-dose rate interstitial with external beam irradiation for localized prostate cancer—Results of a prospective trial. Radiother Oncol. 1998;48:197–202
  28. Kestin L, Vicini F, Martinez AA, et al.  Practical application of biochemical failure definitions (What to do and when to do it). Int J Radiat Oncol Biol Phys. 2002;53:304–315

PII: S0360-3016(03)02347-2

doi: 10.1016/j.ijrobp.2003.11.035

International Journal of Radiation Oncology * Biology * Physics
Volume 59, Issue 3 , Pages 684-690 , 1 July 2004

Article Tools

* Image Usage & Resolution